Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety

Phase 3positiveCentanafadinePositive

AI Analysis

Summary

Otsuka Pharmaceutical announced positive topline results from a Phase 3b study (NCT06973577) evaluating centanafadine in adults with ADHD and comorbid anxiety. The positive outcome supports advancement toward potential regulatory approval of this investigational treatment.

Clinical Trial Data

Phase

Phase 3b

Primary Endpoint

Met

NCT ID

NCT06973577

Outcome Details

Positive topline results in Phase 3b study

Importance:7/10

Sentiment:

0.85

Phase 3b resultsPositive dataADHDAnxietyCentanafadine

Related Companies

$OTSKF $OTSKF

Read the original article

Published by Drugs.com Clinical Trial Results on June 25, 2026 12:06 AM

Read Original